Precision Business Insights
Portfolio

 

Research Reports

Noninvasive Cancer Diagnostics Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Noninvasive Cancer Diagnostics Market By Product (Tests Kits & Reagents and Consumables) By Application (Lung Cancer, Breast Cancer, Solid tumors, Blood cancer, Others), By Technique (Immunochemistry/Immunoassay, Molecular Diagnostics, Clinical Chemistry, and Others), Distribution Channel (Hospitals, Diagnostic Center, Oncology Centers and Others) and Geography.

 

Market Outline: Noninvasive Cancer Diagnostics Market

 

The noninvasive technique is a procedure that does not require insertion of an instrument through the skin. With the advancements in the technology, there are various treatment procedures that are being used. The advent of the modern diagnostic techniques helps in the detection of cancer. The noninvasive techniques play a vital role in the diagnosis of cancer replacing the invasive tests.

 

Increase in the prevalence of chronic diseases such as cancer is the key factor attributed for the growth of the noninvasive cancer diagnostics market. The technological advancements play a vital role in the development of the noninvasive techniques. Rising demand for the noninvasive and minimally invasive diagnosis is adding fuel for the growth of the market. The growing geriatric population along with growing health issues and rising awareness among the patient population regarding various treatment options is boosting the growth of the noninvasive cancer diagnostics market. The initiation taken by the government and non-profitable organizations to create awareness regarding the early diagnosis of the disease is anticipated to drive the growth of the noninvasive cancer diagnostics market.

 

Global noninvasive cancer diagnostics market was valued at US $ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) over 2018 to 2024

 

Market Scope: Noninvasive Cancer Diagnostics Market

Noninvasive cancer diagnostics market is segmented based on the product type, application, and technique

Based on the product, the market is segmented into the following:

  • Test Kits & Reagents
  • Consumables

Based on the application, the market is segmented into the following:

  • Lung Cancer
  • Breast Cancer
  • Solid tumors
  • Blood cancer
  • Others

Based on the technique, the market is segmented into the following:

  • Immunochemistry/Immunoassay
  • Molecular Diagnostics
  • Clinical Chemistry
  • Others

Based on distribution channel, the market is segmented into:

  • Hospitals
  • Diagnostic Centers
  • Oncology Centers
  • Others

 

Regional Analysis:  Noninvasive Cancer Diagnostics Market

Geographically, global noninvasive cancer diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America noninvasive cancer diagnostics market is the dominating market when compared with that of the other regional markets. Owing to its technological advancements and the deep-rooted healthcare infrastructure, the noninvasive cancer diagnostics market is growing significantly in this region. The increase in the awareness among the people regarding the modern treatment methods is boosting the growth of the market in this region. According to American Cancer Society, there were more than 1,660,290 new cases diagnosed in 2013. The well-structured reimbursement policies are enhancing the growth of the market in this region.

 

Competition Assessment: Noninvasive Cancer Diagnostics Market

  • Digene Corporation (U.S.)
  • Gen-Probe Incorporated (U.S.)
  • IVDiagnostics, Inc. (U.S.)
  • A&G Pharmaceutical, Inc. (U.S.)
  • Affymetrix Inc. (U.S.)
  • AVIVA Biosciences Corporation (U.S.)
  • BIOVIEW Inc. (U.S.)
  • Laboratory Corporation of America Holdings (LabCorp) (U.S.)
  • Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)

 

Notable Market Developments:

In May 2018, FDA has approved first Non-Invasive DNA screening test for colorectal cancer

 

Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (the USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentian, Venezula, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Digene Corporation (U.S.)
  • Gen-Probe Incorporated (U.S.)
  • IVDiagnostics, Inc. (U.S.)
  • A&G Pharmaceutical, Inc. (U.S.)
  • Affymetrix Inc. (U.S.)
  • AVIVA Biosciences Corporation (U.S.)
  • BIOVIEW Inc. (U.S.)
  • Laboratory Corporation of America Holdings (LabCorp) (U.S.)
  • Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

Ask An Analyst

$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials